Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Atika Capital Management LLC

Atika Capital Management LLC increased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 40.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 136,500 shares of the company’s stock after purchasing an additional 39,500 shares during the period. Atika Capital Management LLC owned approximately 0.21% of Kymera Therapeutics worth $5,491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after buying an additional 688,967 shares during the period. Vanguard Group Inc. raised its position in Kymera Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company’s stock valued at $196,617,000 after acquiring an additional 133,546 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Kymera Therapeutics by 5.0% in the fourth quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company’s stock valued at $44,484,000 after acquiring an additional 52,263 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Kymera Therapeutics by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company’s stock worth $15,577,000 after purchasing an additional 20,346 shares in the last quarter. Finally, Schroder Investment Management Group grew its stake in shares of Kymera Therapeutics by 14.1% during the 4th quarter. Schroder Investment Management Group now owns 163,896 shares of the company’s stock worth $6,444,000 after purchasing an additional 20,204 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. BTIG Research began coverage on Kymera Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $60.00 target price on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. HC Wainwright lifted their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Stephens restated an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, Citigroup started coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $52.00 target price on the stock. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.36.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the sale, the insider now owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,788 shares of company stock worth $455,202 in the last ninety days. 15.82% of the stock is owned by insiders.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $22.07 on Friday. The stock’s 50 day simple moving average is $34.02 and its 200-day simple moving average is $41.02. The stock has a market cap of $1.43 billion, a P/E ratio of -9.43 and a beta of 2.22. Kymera Therapeutics, Inc. has a 1-year low of $21.40 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. As a group, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.